 Cellular Biomedicine Group, Inc. NASDAQ: CBMG CBMG or the Company, a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019. 